Literature DB >> 33420357

Interleukin-6 mediates neutrophil mobilization from bone marrow in pulmonary hypertension.

Stephen Y Chan1, Partha Dutta2,3, Jonathan Florentin4, Jingsi Zhao4, Yi-Yin Tai4, Sathish Babu Vasamsetti4, Scott P O'Neil4, Rahul Kumar5, Anagha Arunkumar4, Annie Watson4, John Sembrat4,6, Grant C Bullock4,7, Linda Sanders8, Biruk Kassa5, Mauricio Rojas4,6, Brian B Graham8.   

Abstract

Myeloid cells, such as neutrophils, are produced in the bone marrow in high quantities and are important in the pathogenesis of vascular diseases such as pulmonary hypertension (PH). Although neutrophil recruitment into sites of inflammation has been well studied, the mechanisms of neutrophil egress from the bone marrow are not well understood. Using computational flow cytometry, we observed increased neutrophils in the lungs of patients and mice with PH. Moreover, we found elevated levels of IL-6 in the blood and lungs of patients and mice with PH. We observed that transgenic mice overexpressing Il-6 in the lungs displayed elevated neutrophil egress from the bone marrow and exaggerated neutrophil recruitment to the lungs, resulting in exacerbated pulmonary vascular remodeling, and dysfunctional hemodynamics. Mechanistically, we found that IL-6-induced neutrophil egress from the bone marrow was dependent on interferon regulatory factor 4 (IRF-4)-mediated CX3CR1 expression in neutrophils. Consequently, Cx3cr1 genetic deficiency in hematopoietic cells in Il-6-transgenic mice significantly reduced neutrophil egress from bone marrow and decreased neutrophil counts in the lungs, thus ameliorating pulmonary remodeling and hemodynamics. In summary, these findings define a novel mechanism of IL-6-induced neutrophil egress from the bone marrow and reveal a new therapeutic target to curtail neutrophil-mediated inflammation in pulmonary vascular disease.

Entities:  

Keywords:  CX3CR1; IL-6; inflammation; neutrophil; pulmonary hypertension

Mesh:

Substances:

Year:  2021        PMID: 33420357      PMCID: PMC8027442          DOI: 10.1038/s41423-020-00608-1

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  59 in total

1.  Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension.

Authors:  Eleni Vergadi; Mun Seog Chang; Changjin Lee; Olin D Liang; Xianlan Liu; Angeles Fernandez-Gonzalez; S Alex Mitsialis; Stella Kourembanas
Journal:  Circulation       Date:  2011-04-25       Impact factor: 29.690

2.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.

Authors:  Frank Tacke; David Alvarez; Theodore J Kaplan; Claudia Jakubzick; Rainer Spanbroek; Jaime Llodra; Alexandre Garin; Jianhua Liu; Matthias Mack; Nico van Rooijen; Sergio A Lira; Andreas J Habenicht; Gwendalyn J Randolph
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage.

Authors:  Maria G Frid; Jacqueline A Brunetti; Danielle L Burke; Todd C Carpenter; Neil J Davie; John T Reeves; Mark T Roedersheimer; Nico van Rooijen; Kurt R Stenmark
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

4.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.

Authors:  M Romano; M Sironi; C Toniatti; N Polentarutti; P Fruscella; P Ghezzi; R Faggioni; W Luini; V van Hinsbergh; S Sozzani; F Bussolino; V Poli; G Ciliberto; A Mantovani
Journal:  Immunity       Date:  1997-03       Impact factor: 31.745

5.  Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension.

Authors:  Takahiro Hashimoto-Kataoka; Naoki Hosen; Takashi Sonobe; Yoh Arita; Taku Yasui; Takeshi Masaki; Masato Minami; Tadakatsu Inagaki; Shigeru Miyagawa; Yoshiki Sawa; Masaaki Murakami; Atsushi Kumanogoh; Keiko Yamauchi-Takihara; Meinoshin Okumura; Tadamitsu Kishimoto; Issei Komuro; Mikiyasu Shirai; Yasushi Sakata; Yoshikazu Nakaoka
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-04       Impact factor: 11.205

6.  Transforming growth factor-β signaling promotes pulmonary hypertension caused by Schistosoma mansoni.

Authors:  Brian B Graham; Jacob Chabon; Liya Gebreab; Jennifer Poole; Elias Debella; Laura Davis; Takeshi Tanaka; Linda Sanders; Nina Dropcho; Angela Bandeira; R William Vandivier; Hunter C Champion; Ghazwan Butrous; Xiao-Jing Wang; Thomas A Wynn; Rubin M Tuder
Journal:  Circulation       Date:  2013-08-19       Impact factor: 29.690

7.  Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice.

Authors:  Christophe Combadière; Stéphane Potteaux; Mathieu Rodero; Tabassome Simon; Adeline Pezard; Bruno Esposito; Régine Merval; Amanda Proudfoot; Alain Tedgui; Ziad Mallat
Journal:  Circulation       Date:  2008-03-17       Impact factor: 29.690

8.  Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension.

Authors:  Kurt W Prins; Stephen L Archer; Marc Pritzker; Lauren Rose; E Kenneth Weir; Alok Sharma; Thenappan Thenappan
Journal:  J Heart Lung Transplant       Date:  2017-09-01       Impact factor: 10.247

9.  Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension.

Authors:  Nathalie Mouraret; Elisabeth Marcos; Shariq Abid; Guillaume Gary-Bobo; Mirna Saker; Amal Houssaini; Jean-Luc Dubois-Rande; Laurent Boyer; Jorge Boczkowski; Geneviève Derumeaux; Valérie Amsellem; Serge Adnot
Journal:  Circulation       Date:  2013-03-19       Impact factor: 29.690

10.  Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension.

Authors:  Hirofumi Sawada; Toshie Saito; Nils P Nickel; Tero-Pekka Alastalo; Jason P Glotzbach; Roshelle Chan; Leila Haghighat; Gabriele Fuchs; Michael Januszyk; Aiqin Cao; Ying-Ju Lai; Vinicio de Jesus Perez; Yu-Mee Kim; Lingli Wang; Pin-I Chen; Edda Spiekerkoetter; Yoshihide Mitani; Geoffrey C Gurtner; Peter Sarnow; Marlene Rabinovitch
Journal:  J Exp Med       Date:  2014-01-20       Impact factor: 14.307

View more
  9 in total

Review 1.  Endothelial Senescence: A New Age in Pulmonary Hypertension.

Authors:  Miranda K Culley; Stephen Y Chan
Journal:  Circ Res       Date:  2022-03-17       Impact factor: 17.367

2.  Plasma Cell-Free DNA Predicts Survival and Maps Specific Sources of Injury in Pulmonary Arterial Hypertension.

Authors:  Sean Agbor-Enoh; Michael A Solomon; Samuel B Brusca; Jason M Elinoff; Yvette Zou; Moon Kyoo Jang; Hyesik Kong; Cumhur Y Demirkale; Junfeng Sun; Fayaz Seifuddin; Mehdi Pirooznia; Hannah A Valantine; Carl Tanba; Abhishek Chaturvedi; Grace M Graninger; Bonnie Harper; Li-Yuan Chen; Justine Cole; Manreet Kanwar; Raymond L Benza; Ioana R Preston
Journal:  Circulation       Date:  2022-08-25       Impact factor: 39.918

3.  Loss of Amphiregulin drives inflammation and endothelial apoptosis in pulmonary hypertension.

Authors:  Jonathan Florentin; Jingsi Zhao; Yi-Yin Tai; Wei Sun; Lee L Ohayon; Scott P O'Neil; Anagha Arunkumar; Xinyi Zhang; Jianhui Zhu; Yassmin Al Aaraj; Annie Watson; John Sembrat; Mauricio Rojas; Stephen Y Chan; Partha Dutta
Journal:  Life Sci Alliance       Date:  2022-06-22

4.  Neutrophilic inflammation promotes SARS-CoV-2 infectivity and augments the inflammatory responses in airway epithelial cells.

Authors:  B A Calvert; E J Quiroz; Z Lorenzana; N Doan; S Kim; C N Senger; W D Wallace; M P Salomon; J Henley; A L Ryan
Journal:  bioRxiv       Date:  2022-06-06

5.  Differential Signature of the Microbiome and Neutrophils in the Oral Cavity of HIV-Infected Individuals.

Authors:  Eliana Perez Rosero; Samantha Heron; Juan Jovel; Conar R O'Neil; Shannon Lee Turvey; Pallavi Parashar; Shokrollah Elahi
Journal:  Front Immunol       Date:  2021-11-09       Impact factor: 7.561

6.  In Vitro Erythropoiesis at Different pO2 Induces Adaptations That Are Independent of Prior Systemic Exposure to Hypoxia.

Authors:  Greta Simionato; Antonia Rabe; Joan Sebastián Gallego-Murillo; Carmen van der Zwaan; Arie Johan Hoogendijk; Maartje van den Biggelaar; Giampaolo Minetti; Anna Bogdanova; Heimo Mairbäurl; Christian Wagner; Lars Kaestner; Emile van den Akker
Journal:  Cells       Date:  2022-03-23       Impact factor: 6.600

7.  Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.

Authors:  Chao Qu; Wei Feng; Qi Zhao; Qi Liu; Xing Luo; Gang Wang; Meng Sun; Zhibo Yao; Yufei Sun; Shenglong Hou; Chunyang Zhao; Ruoxi Zhang; Xiufen Qu
Journal:  Front Med (Lausanne)       Date:  2022-03-04

8.  Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial.

Authors:  Camilla Huse; Anne Kristine Anstensrud; Annika E Michelsen; Thor Ueland; Kaspar Broch; Sindre Woxholt; Kuan Yang; Kapil Sharma; Ingvild Maria Tøllefsen; Bjørn Bendz; Brage Høyem Amundsen; Jan Kristian Damås; Erlend Sturle Berg; Elisabeth Bjørkelund; Ana Quiles-Jiménez; Vigdis Bjerkeli; Christina Bendz; Ola Kleveland; Knut Haakon Stensaeth; Anders Opdahl; Nils-Einar Kløw; Geir Øystein Andersen; Rune Wiseth; Bente Halvorsen; Lars Gullestad; Ingebjørg Seljeflot; Pål Aukrust; Liv Osnes; Tuva B Dahl
Journal:  EBioMedicine       Date:  2022-04-30       Impact factor: 11.205

9.  Bioinformatic exploration of the immune related molecular mechanism underlying pulmonary arterial hypertension.

Authors:  Ruina Huang; Xifeng Zheng; Junxian Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.